Q-omics provides the consensus-scored MIR6071 profile across patient tissues and cancer cell-line models. MIR6071 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MIR6071 is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, MIR6071 RNA expression shows 12,509 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, LUSC, and THYM as cancer lineages where MIR6071 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6071 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6071 survival associations across molecular data types. MIR6071 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6071 RNA expression–survival associations across cancer types. High MIR6071 expression shows unfavorable associations in LUSC and CESC, but favorable associations in KIRP, PAAD, LGG and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MIR6071 RNA expression.
This table summarizes MIR6071 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6071. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6071 shows lower tumor expression in LUSC, THCA, LUAD, BRCA, KICH and STAD. The LUSC box plot shows higher MIR6071 RNA expression in normal versus tumor tissue (log2 FC = −2.331, t-test p < 0.001).
This table shows molecular features associated with MIR6071 in patient tissues and cancer cell lines. In patient samples, MIR6071 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
